Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Enrolling By Invitation NCT06868459

Pressure-enabled Retrograde Occlusive Therapy With Embolization for Control of Thyroid Disease (PROTECT Registry): A Multicenter Registry

Conditions: Hyperthyroidism; Goiter, Multinodular Goiter, Thyroid Nodules, Thyroid Disease, Hyperthyroidism, Toxic Multinodular Goiter

Sex: All
Ages: 18 Years – 89 Years
Healthy volunteers: No
Enrollment: 100
Sponsor: Sarasota Memorial Health Care System

Location: Mayo Clinic Jacksonville Florida

Summary

Multi-center registry study to evaluate disease-related quality of life outcomes of thyroid embolization via pressure-enabled delivery (PED-TAE). Additional technical success data on parenchymal volume reduction, thyroid function tests changes and post-procedural complications will be recorded. Data will be collected for patients who have undergone PED-TAE using the TriNav Infusion System at participating sites. The registry study will include up to 10 sites, with Sarasota Memorial Health Care System acting as the lead site responsible for maintaining and monitoring the study database.

Eligibility Criteria

Inclusion Criteria: 1. Adults, 18 years and or older and 89 years or younger 2. Having undergone PED-TAE using the TriNav Infusion System 3. Meeting one of the following criteria: 1. Documented subclinical and or clinical hyperthyroidism in the presence of a toxic multinodular goiter or a toxic nodule \> 20 ml 2. Patients' ineligible or refusing surgery, radio-iodine therapy or percutaneous ablation 3. Non-functioning multinodular goiters or nodule causing compressive symptoms including but not limited to neck pain, dysphagia, stridor, exercise induced dyspnea and/or pressure symptoms 4. Bethesda category 2-3 (benign, or atypia or follicular lesion of undetermined significance) on 2 separate fine-needle aspiration biopsy (FNAB) results with a benign molecular profile with patient declining surgical resection Exclusion Criteria: 1. Renal insufficiency 2. Unable to tolerate angiography including pregnancy and severe allergy to contrast media 3. Bethesda 4-6 on FNAB (suspicious for follicular neoplasm, suspicious for malignancy, or malignant) 4. \89 years old 5. Graves' disease or inflammatory thyroiditis (Hashimoto's) or other condition with the presence of an extensive collateral network as demonstrated or initial angiography 6. Presence of a bovine arch or any other anatomical variant with no inferior thyroid artery present 7. Prior thyroid thermal ablation

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06868459). StuddyBuddy aggregates publicly available trial information.